Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Haemorrhage/shock · TBI
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
MouseHaemorrhage/shockUnspecifiedCx3cr1/Ccr2 double transgenic miceMale and female
Model: Experimental subarachnoid haemorrhage with early brain injury
Activated microglia appeared in cortex by 24 h and increased at 48 and 72 h, while monocyte infiltration was not seen until 72 h. TAT-Pep5 significantly reduced microglial activation, neuroinflammation and early brain injury from 24 to 72 h.
Extraction: extract · Supplied extraction confidence: 0.58. Machine-extracted fields require source verification.
MouseTBIControlled cortical impactC57BL/6 background, including NGFR(-/-) mice lacking the proneurotrophin-binding site of p75NTR and NGFR(+/+) wild type littermatesmale and female
Model: Controlled cortical impact (CCI) traumatic brain injury
p75NTR mRNA was induced nine-fold by TBI. Genetic deletion of the proneurotrophin-binding site reduced lesion volume by 29% at 24 h and 21% at 5 days and improved motor coordination at 24 h. Pharmacological inhibition with TAT-Pep5 reduced lesion volume by 18% at 24 h.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
